Cancer Can Expose the Hidden Limits of a Medicare Advantage Plan

A Medicare plan can look perfectly adequate when healthcare consists of annual physicals, routine prescriptions and an occasional specialist visit. Cancer changes the test. Suddenly, the important questions are not whether a plan offers dental benefits or a $0 premium, but whether a particular surgeon is in-network, whether advanced imaging will be approved quickly and whether the treatment an oncologist recommends can actually be obtained at the hospital where the patient wants to receive it.

Prostate cancer provides a useful example because patients can have several legitimate treatment options depending on the stage and aggressiveness of the disease, age, overall health and personal priorities. Those options can include active surveillance, surgery, conventional external-beam radiation, stereotactic body radiation therapy, brachytherapy, proton therapy and, in more advanced disease, systemic therapies such as hormone treatment or chemotherapy. Original Medicare and Medicare Advantage both provide Medicare-covered benefits, but the path to obtaining those benefits can differ considerably because Medicare Advantage plans may use provider networks and prior authorization.

The distinction does not mean Medicare Advantage refuses to treat cancer or that Original Medicare automatically approves every treatment a doctor recommends. The more important issue is access. A benefit can technically exist while the patient still faces an insurer’s authorization process, a restricted provider network or additional documentation requirements before the desired treatment proceeds.

Proton Therapy Shows Why the Details Matter

Proton therapy is an advanced form of external-beam radiation. Conventional photon radiation deposits radiation along its path through the body, while proton beams can be designed to deliver much of their dose at a particular depth before falling off sharply. That physical characteristic can reduce radiation exposure to surrounding tissue in certain situations and is one reason radiation oncologists may consider proton therapy when critical organs sit near the treatment area.

The scientific evidence for prostate cancer, however, requires an important qualification. Proton therapy should not be presented as universally safer or more effective than modern photon radiation. A multicenter randomized phase III trial involving 450 men with low- or intermediate-risk localized prostate cancer found no meaningful difference between proton therapy and intensity-modulated radiation therapy in patient-reported bowel, urinary or sexual function. Five-year progression-free survival was also virtually identical: 93.4% with proton therapy and 93.7% with IMRT.

That does not make proton therapy pointless. Individual anatomy, previous radiation exposure and the location of nearby organs can still make its dose characteristics valuable for particular patients. Medicare coverage policies also recognize prostate cancer as a potential indication under certain circumstances. One current Medicare local coverage determination includes nonmetastatic prostate cancer among conditions that can support proton therapy when medical necessity and patient-selection requirements are documented.

The critical nuance is that Medicare does not have one simple national rule saying every prostate cancer patient is entitled to proton therapy whenever a physician prefers it. Coverage can depend on the clinical facts, documentation and the applicable Medicare Administrative Contractor’s local coverage policy. That makes the difference between Original Medicare and Medicare Advantage less about whether proton therapy is universally “covered” and more about how many additional barriers exist between the physician’s recommendation and treatment.

Prior Authorization Adds Another Decision Maker

Medicare Advantage plans are allowed to use prior authorization for certain services. Before treatment proceeds, the physician or facility may need to submit documentation establishing that the request meets the plan’s coverage criteria. The process is designed partly to prevent unnecessary care and control costs, but federal regulators have repeatedly raised concerns about situations in which beneficiaries were initially denied services that should have been covered.

A widely cited 2022 investigation by the Department of Health and Human Services Office of Inspector General examined denied Medicare Advantage prior-authorization requests and found that 13% of the sampled denials met Medicare coverage rules. In other words, OIG reviewers concluded that those services likely would have been approved under Original Medicare. The report found cases in which plans applied additional internal criteria or determined that medical records were insufficient even though OIG physician reviewers believed the documentation supported medical necessity.

That 13% figure should not be interpreted to mean that 13% of all Medicare Advantage care is improperly denied. It applies specifically to the sample of denied requests reviewed by OIG. The finding nevertheless matters because serious illnesses generate precisely the kinds of expensive services that commonly receive utilization review, including advanced imaging, hospital care, rehabilitation and high-cost therapies.

For a prostate cancer patient, the authorization process might require records establishing the cancer stage, imaging results, previous treatments and why one radiation technique is clinically appropriate. That may be reasonable when the evidence is ambiguous, but the administrative burden can become consequential when the patient and physician are already trying to make a complicated treatment decision under significant emotional pressure.

Appeals Often Work, but Patients Have to Appeal

An initial Medicare Advantage denial does not necessarily settle the matter. Beneficiaries and their physicians have formal appeal rights, and additional medical documentation can result in a decision being reversed.

CMS has reported that Medicare Advantage organizations overturn approximately 80% of denied claims that are appealed to the plan. The same CMS data showed that fewer than 4% of denied claims were appealed, raising concern that many potentially reversible denials simply remained in place because no challenge was filed.

Those statistics apply broadly to Medicare Advantage claims rather than specifically to oncology, so they should not be interpreted as an 80% cancer-treatment appeal success rate. They do demonstrate why patients should not automatically accept a denial as the final answer. Oncology practices often have authorization specialists, financial counselors or other staff who understand how to submit additional records, request peer-to-peer review and pursue expedited appeals when treatment is time-sensitive.

The appeal system itself has also continued evolving. CMS updated its Medicare Advantage and Part D appeals guidance in July 2026, reflecting broader regulatory efforts to tighten coverage-decision and appeals requirements. The reforms may make the system more consistent, but they do not eliminate the practical burden on patients and medical offices trying to reverse an initial decision.

Cancer Networks Can Become More Important Than Premiums

Provider networks are another area where serious illness can reveal a difference that was almost invisible when coverage was selected. Original Medicare generally allows beneficiaries to receive covered care from physicians and hospitals that accept Medicare. Medicare Advantage plans instead commonly use HMO or PPO networks, with the rules for receiving nonemergency out-of-network care depending on the plan.

That distinction can become significant when a patient wants evaluation at a specialized cancer center or from a physician who performs a high volume of one particular procedure. A local oncology practice may be entirely capable of providing excellent care, but some patients understandably want a second opinion from a larger academic center when the diagnosis or treatment choice is complicated.

An HMO may offer little routine out-of-network coverage, while a PPO may permit it with higher cost sharing. The patient can therefore discover that a physician who “takes Medicare” does not participate in the specific Medicare Advantage plan. The correct question is not simply whether the hospital accepts Medicare, but whether both the physician and facility are participating providers for the exact plan.

For someone choosing coverage while healthy, that network distinction can seem hypothetical. Once cancer appears, it can determine whether seeing the desired specialist is an ordinary covered visit, a substantially more expensive out-of-network service or something the plan will not cover routinely at all.

The Best Treatment Is Not Always a Single Treatment

Prostate cancer also illustrates why insurance flexibility matters even when several effective options exist. For some low-risk cancers, active surveillance may allow the patient to postpone or avoid treatment entirely. Other patients may choose surgery, conventional radiation, stereotactic radiation or brachytherapy depending on tumor characteristics and their priorities regarding urinary, sexual and bowel side effects.

The existence of alternatives can complicate insurance disputes. A plan may conclude that one covered treatment is clinically sufficient even when the physician believes another approach is preferable for the individual patient. That does not automatically mean the insurer is selecting treatment solely because it is cheaper, nor does a physician’s preference automatically establish Medicare coverage. It does mean the patient may need to understand whether the recommended treatment satisfies Medicare criteria and any additional authorization process imposed by the plan.

The proton example is especially useful because the latest randomized evidence demonstrates excellent results with both protons and modern photon therapy for localized low- and intermediate-risk prostate cancer. A coverage disagreement should therefore not be framed as an insurer forcing every patient to accept clearly inferior care. The concern is narrower but still important: whether insurance rules constrain a medically reasonable option that the patient and treating physicians believe is appropriate.

Imaging Can Become the First Bottleneck

Cancer treatment frequently depends on testing performed before the first treatment begins. MRI, CT scans and advanced PET imaging can help establish disease extent, determine whether cancer has spread and guide the choice between surveillance, surgery, radiation and systemic treatment.

When imaging requires prior authorization, administrative delays can occur before the treatment decision itself has even been finalized. Additional records may need to be submitted, an initial request may need revision or a physician may have to explain why a particular test is necessary. If the preferred imaging center sits outside the plan network, the patient may also have to choose another facility or request an exception.

A delay does not automatically mean the cancer outcome will worsen. Prostate cancers vary considerably in aggressiveness, and many cases do not require emergency treatment. The more immediate effect can be uncertainty. A patient who has already heard the word cancer may spend additional days or weeks waiting for the imaging needed to understand exactly what kind of cancer is present and which treatments make sense.

That experience illustrates why authorization should be considered part of healthcare access rather than merely paperwork.

Drug Coverage Adds Another Layer of Complexity

Cancer drugs can be covered through different parts of Medicare depending on how they are administered. Medications delivered in a physician’s office or outpatient facility can fall under Part B, while many medications taken at home are covered through Part D. Prostate cancer treatment can involve both categories as disease becomes more advanced.

Medicare Advantage plans that include prescription coverage can use formularies and utilization-management requirements for Part D drugs. Part B drugs can also face prior-authorization rules under Medicare Advantage. A patient therefore needs to know more than whether the plan has “cancer drug coverage”; the important questions involve the particular medication, its cost-sharing structure and what approval requirements apply.

This becomes especially important because oncology treatment can change. A patient may begin with surgery or radiation and later require hormone therapy or another systemic treatment after recurrence. A plan that appeared inexpensive during the first year of Medicare can produce a very different financial experience once frequent treatment begins.

Drug coverage should therefore be evaluated alongside the medical network rather than treated as a separate issue.

Complex Surgery Can Make Experience More Important

For operations such as radical prostatectomy and other complicated cancer procedures, patients often consider surgeon experience and institutional volume when selecting where to receive care. The physician who performs a procedure repeatedly may offer a level of specialization difficult to replicate at a smaller center, although volume alone does not guarantee a good outcome.

A broad provider network gives patients more ability to seek those specialists. A narrow network can make the decision more constrained, particularly when the desired surgeon practices at an institution that does not contract with the Medicare Advantage plan.

The financial consequences can be substantial. An HMO patient may have no routine coverage for an out-of-network elective surgery, while PPO out-of-network coinsurance can be considerably higher. The patient can then face a choice among using the available network, attempting to obtain an exception or paying significantly more for the preferred specialist.

That does not make a local in-network surgeon inferior. It makes the breadth of the network part of the insurance product, something consumers should evaluate before they know which specialty they may eventually need.

Clinical Trials Have Their Own Coverage Rules

Clinical trials can become important for patients with cancers that are difficult to treat or have returned after standard therapies. Medicare covers routine costs associated with certain qualifying clinical research studies, although the investigational item itself may be paid by the study sponsor or excluded from Medicare coverage depending on the trial.

Medicare Advantage beneficiaries are not automatically barred from participating in Medicare-covered trials. The coverage rules involve coordination between Original Medicare and the Medicare Advantage plan for qualifying research-related services. The practical problem can still involve access when the physicians or institution conducting the trial are outside the plan’s ordinary network.

Patients considering a trial should therefore have the research center verify insurance arrangements before enrollment. The trial coordinator can explain which costs are paid by the sponsor, which are considered routine Medicare-covered care and which expenses remain the patient’s responsibility.

The availability of a clinical trial may be particularly important for advanced cancer, making it another example of why provider geography and network design can matter long after the Medicare plan was originally selected.

Rehabilitation Can Become Another Authorization Fight

Treatment does not always end when the cancer is removed or radiation concludes. Some patients need home health services, inpatient rehabilitation or skilled nursing care after hospitalization or surgery. Medicare Advantage authorization practices around post-acute care have attracted growing federal scrutiny.

In 2026, OIG reported that 19 Medicare Advantage organizations denied 12% of skilled-nursing-facility admission requests examined from June 2024. Only 18% of those denials were appealed, but when they were challenged, the plans overturned 95% in favor of the beneficiary. A separate 2026 OIG review found that the three largest Medicare Advantage organizations had some of the highest denial rates for long-term acute-care hospitals and inpatient rehabilitation facilities, with 36% of appealed long-term acute-care denials and 43% of appealed inpatient-rehabilitation denials overturned.

Those reports were not limited to cancer patients, but they are directly relevant to anyone who might need rehabilitation after serious treatment. A patient’s medical problem can therefore move from one authorization process to another as care progresses from hospital to rehabilitation to home.

The takeaway is not that Medicare Advantage routinely blocks recovery care. It is that patients and families should understand appeal rights and begin discharge planning early when post-acute services are likely to be needed.

Original Medicare Has Its Own Financial Risks

A comparison focused entirely on Medicare Advantage restrictions can make Original Medicare appear simpler than it really is. Original Medicare generally provides broad provider access, but it also leaves beneficiaries responsible for deductibles and coinsurance unless they have Medigap, employer coverage or another supplement.

Part B generally leaves a beneficiary responsible for 20% of the Medicare-approved amount for many covered services after the deductible, and Original Medicare by itself does not have the broad annual out-of-pocket maximum that Medicare Advantage plans provide. Cancer treatment can therefore create meaningful financial exposure for someone relying on Original Medicare without supplemental coverage.

For many retirees, the more realistic comparison is Medicare Advantage versus Original Medicare combined with Medigap and Part D. Medigap can substantially reduce Original Medicare’s cost sharing, but it adds a monthly premium and does not ordinarily include the dental, vision and other supplemental benefits available with many Advantage plans.

Medicare Advantage can therefore remain a sensible choice for someone who prioritizes lower monthly premiums and has confidence in the local network. The concern is choosing it primarily for the premium without understanding what the plan may require when medical care becomes complicated.

Switching After Cancer May Not Be as Easy as It Sounds

Some beneficiaries assume they can use Medicare Advantage while healthy and switch to Original Medicare with Medigap if they later develop a serious condition. Returning to Original Medicare may be possible during an eligible enrollment period, but obtaining the desired Medigap policy afterward is a separate matter.

Federal law provides a protected six-month Medigap Open Enrollment Period beginning when someone is at least 65 and first enrolled in Part B. Outside that period, beneficiaries may need to pass medical underwriting unless they qualify for a guaranteed-issue right or their state provides additional protections. A serious health condition can therefore make switching into Medigap more difficult in states that permit underwriting.

That does not mean cancer automatically makes a Medigap application impossible. State rules differ, guaranteed-issue situations exist and certain Medicare Advantage trial rights provide additional protections. It does mean beneficiaries should not assume that every Medicare configuration remains equally available after health changes.

The long-term flexibility of the original Medicare decision deserves consideration before a diagnosis forces the issue.

Ask the Cancer Questions Before You Need the Answers

A Medicare comparison should include a hypothetical bad-health year rather than only the healthcare someone uses today. That means looking beyond premiums and asking which major regional hospitals, oncology groups and specialty centers participate in the plan. Beneficiaries should also examine whether advanced imaging, radiation, Part B drugs and post-acute care commonly require authorization.

Someone considering Medicare Advantage should know how out-of-network care works, what the medical maximum out-of-pocket exposure is and how the appeals process operates. Someone considering Original Medicare with Medigap should understand the combined premiums, prescription coverage and whether the desired supplement is affordable over the long term.

Cancer makes those differences visible because treatment is rarely one event. It can involve imaging, pathology, surgery, radiation, medications, second opinions, rehabilitation and sometimes clinical trials. Every stage can interact differently with insurance rules.

The best Medicare plan is therefore not simply the one that covers cancer on paper. It is the one whose rules, provider access and financial structure the beneficiary would be comfortable navigating if cancer actually occurred.

The Important Difference Is Access, Not Whether Cancer Is Covered

Medicare Advantage plans are required to provide Medicare-covered benefits, and millions of beneficiaries receive successful cancer treatment through them every year. The strongest criticism is not that Medicare Advantage excludes cancer, but that managed-care tools can affect the path to obtaining particular services.

Federal oversight provides legitimate reason for concern. OIG found that 13% of sampled denied prior-authorization requests met Medicare coverage requirements, while CMS has reported that plans reverse a large majority of denied claims that beneficiaries actually appeal. At the same time, new evidence on proton therapy demonstrates why patients and advocates should avoid assuming every expensive technology is medically superior simply because it is newer or more targeted. For localized low- and intermediate-risk prostate cancer, proton therapy and modern IMRT produced similarly excellent outcomes in a randomized trial.

Those two facts can coexist. Insurers should not improperly block medically necessary care, and not every physician-preferred or technologically advanced treatment is automatically better than covered alternatives.

For beneficiaries, that makes the Medicare decision less ideological and more practical. Which doctors can you see? Which hospitals can you use? Which services require permission? What happens if the recommendation is denied? How much flexibility would you want after a serious diagnosis?

Those questions may seem unimportant when Medicare begins and health is good. After cancer appears, they can become the questions that matter most.